Global Irritable Bowel Syndrome Treatment Market - 2025-2033
Global Irritable Bowel Syndrome Treatment Market Overview
The global irritable bowel syndrome treatment market reached US$ 3.61 billion in 2024 and is expected to reach US$ 7.68 billion by 2033, growing at a CAGR of 8.8% during the forecast period 2025-2033.
Irritable bowel syndrome (IBS) is a condition with high unmet needs. Globally, 5% to 10% of the population suffers from this condition. The market for IBS is experiencing significant growth driven by factors such as rising prevalence due to increasing stress levels, unhealthy eating habits, sedentary lifestyles, and an aging population. However, lack of awareness, underdiagnosis in low-income and emerging countries, and lack of disease-modifying therapies can significantly hamper the market growth. The new treatment modalities, such as microbiome-based therapies, can provide new avenues of treatment in the future.
Global Irritable Bowel Syndrome Treatment Market Dynamics: Drivers & Restraints
The rising prevalence of irritable bowel syndrome is driving the market growth
Several epidemiological studies were conducted globally to define the population cohorts living with the condition. However, based on the diagnostic criteria employed (Rome III or Rome IV), the prevalence may vary substantially from study to study. However, according to the International Foundation for Gastrointestinal Disorders (IFFGD), irritable bowel syndrome affects approximately 5% to 10% of the world's population, making it one of the most common gastrointestinal disorders. According to its survey results, the majority of the population diagnosed are women, rather than men.
Irritable bowel syndrome is a condition exacerbated by various causes. It can be triggered by changes in lifestyle, excessive stress, consumption of processed foods, mental health conditions, experiencing traumatic events, etc. Anything that disrupts the brain-gut axis can exacerbate IBS. For instance, an epidemiological study conducted in Saudi Arabia, and published in the Springer Nature journal in July 2024, has stated that the key risk factors include anxiety, stress, family history, depression, gastroesophageal disease, etc.
Globally, all population groups, especially adults, are experiencing stress and mental health issues, which are one of the key contributing factors for IBS. A study published in the BMC Public Health journal in December 2024 stated that among 77 evaluated countries, approximately 30 to 50% of the population reported experiencing psychological stress. Among these countries, 85% have reported worsening of the psychological stress levels over the past decade. This indicates that a significant portion of the global population is struggling with some form of mental health issues.
This signifies the proportion of the population who are at risk of IBS. As the global population ages, with significant changes in lifestyle, food habits, and stress levels, the IBS prevalence is expected to rise substantially, propelling the demand for advanced therapeutics in the forecast period.
Underdiagnosis of irritable bowel syndrome may hamper the market growth
Despite the high prevalence of IBS, the diagnosis rate is substantially low, especially in low and middle-income countries. Lack of awareness, misconception of IBS symptoms with other common gastrointestinal conditions, lack of proper biomarkers, and a limited number of diagnostic tests are all factors that contribute to the underdiagnosis of the condition.
A study published in the Neurogastroenterology & Motility journal in November 2024 stated that among the surveyed primary healthcare physicians in the US and Europe, 80% of them have the perception that 80% of the IBS patients are underdiagnosed in a primary healthcare setting. This underdiagnosis can significantly restrain the market growth by limiting the number of patients who receive appropriate treatment.
Global Irritable Bowel Syndrome Treatment Market Segment Analysis
The global irritable bowel syndrome treatment market is segmented based on disease type, drug class, and region.
Secretagogues in the drug class segment accounted for 32.9% of the market share in 2024 in the global irritable bowel syndrome treatment market
Secretagogues are a class of products that act by stimulating the release of bodily substances like hormones, fluids, enzymes, etc. In irritable bowel syndrome, the secretagogues act by inducing the release of intestinal fluids, which will aid in improving the bowel movement and reducing constipation. These drugs are currently approved by the regulatory bodies, such as the FDA, for use in IBS patients. These include drugs such as linaclotide (Linzess/Constella), lubiprostone (Amitiza), and plecanatide (Trulance). These drugs combinedly generated approximately 1.2 billion sales in 2024.
Due to the presence of brand exclusivity, manufacturers hold greater power in deciding the product price, hence generating higher revenues for their products. Although not widely adopted across the world, and majority of the patient population prefers the generic medication, especially in low & middle-income countries, this segment is poised to grow due to increasing awareness, clinical efficacy, and expansion into growing markets.
Global Irritable Bowel Syndrome Treatment Market Geographical Analysis
North America dominated the irritable bowel syndrome treatment market with the highest share of 45.3% in 2024
The disease burden of IBS is high in North America, especially in the U.S., due to an aging population, increasing stress levels among the population, unhealthy eating habits, mental health conditions, and many other factors. According to the American College of Gastroenterology, 1 in every 20 people in the US suffers from IBS.
In addition to this high disease burden, the U.S. boasts its advanced healthcare industry. There are several advanced drugs available in the U.S. market that are approved specifically for the condition. Manufacturers are constantly involved in launching novel therapies for IBS in the country. For instance, in April 2022, Ardelyx, Inc. announced the U.S. launch of IBSRELA for the treatment of IBS-C in adults. This drug acts by inhibiting NHE3 (Sodium-Hydrogen Exchanger 3), a novel mechanism targeting to treat constipation in IBS patients. This drug has become the first to be approved in the U.S. after 10 years, that is focusing on a novel mechanism.
Moreover, the most popular drugs for IBS, i.e., secretagogues, are widely available in the United States, and in fact, they generate a major portion of their revenue from the country. For instance, linaclotide sold under the brand name Linzess, by Ironwood Pharmaceuticals, Inc. and AbbVie, has generated a total sales of 954 million in 2024, out of which 96% is from the United States. This represents the highest for advanced therapies in the United States. All these factors strongly contribute to the region’s dominance in the global irritable bowel syndrome treatment market.
Global Irritable Bowel Syndrome Treatment Market Competitive Landscape (Major Players)
The major players in the irritable bowel syndrome treatment market are Procter & Gamble, Haleon Group of Companies., Teva Pharmaceutical Industries Ltd., Ironwood Pharmaceuticals, Inc., AbbVie., Salix Pharmaceuticals, Foundation Consumer Brands., Kenvue Brands LLC., Pfizer Inc., Upsher-Smith Laboratories, LLC., Sanofi, Bayer AG, Atlantis Consumer Healthcare Inc., Alfasigma Group, Takeda Pharmaceutical Company Limited., and Ardelyx. among others.
Global Irritable Bowel Syndrome Treatment Market Key Development
The global irritable bowel syndrome treatment market reached US$ 3.61 billion in 2024 and is expected to reach US$ 7.68 billion by 2033, growing at a CAGR of 8.8% during the forecast period 2025-2033.
Irritable bowel syndrome (IBS) is a condition with high unmet needs. Globally, 5% to 10% of the population suffers from this condition. The market for IBS is experiencing significant growth driven by factors such as rising prevalence due to increasing stress levels, unhealthy eating habits, sedentary lifestyles, and an aging population. However, lack of awareness, underdiagnosis in low-income and emerging countries, and lack of disease-modifying therapies can significantly hamper the market growth. The new treatment modalities, such as microbiome-based therapies, can provide new avenues of treatment in the future.
Global Irritable Bowel Syndrome Treatment Market Dynamics: Drivers & Restraints
The rising prevalence of irritable bowel syndrome is driving the market growth
Several epidemiological studies were conducted globally to define the population cohorts living with the condition. However, based on the diagnostic criteria employed (Rome III or Rome IV), the prevalence may vary substantially from study to study. However, according to the International Foundation for Gastrointestinal Disorders (IFFGD), irritable bowel syndrome affects approximately 5% to 10% of the world's population, making it one of the most common gastrointestinal disorders. According to its survey results, the majority of the population diagnosed are women, rather than men.
Irritable bowel syndrome is a condition exacerbated by various causes. It can be triggered by changes in lifestyle, excessive stress, consumption of processed foods, mental health conditions, experiencing traumatic events, etc. Anything that disrupts the brain-gut axis can exacerbate IBS. For instance, an epidemiological study conducted in Saudi Arabia, and published in the Springer Nature journal in July 2024, has stated that the key risk factors include anxiety, stress, family history, depression, gastroesophageal disease, etc.
Globally, all population groups, especially adults, are experiencing stress and mental health issues, which are one of the key contributing factors for IBS. A study published in the BMC Public Health journal in December 2024 stated that among 77 evaluated countries, approximately 30 to 50% of the population reported experiencing psychological stress. Among these countries, 85% have reported worsening of the psychological stress levels over the past decade. This indicates that a significant portion of the global population is struggling with some form of mental health issues.
This signifies the proportion of the population who are at risk of IBS. As the global population ages, with significant changes in lifestyle, food habits, and stress levels, the IBS prevalence is expected to rise substantially, propelling the demand for advanced therapeutics in the forecast period.
Underdiagnosis of irritable bowel syndrome may hamper the market growth
Despite the high prevalence of IBS, the diagnosis rate is substantially low, especially in low and middle-income countries. Lack of awareness, misconception of IBS symptoms with other common gastrointestinal conditions, lack of proper biomarkers, and a limited number of diagnostic tests are all factors that contribute to the underdiagnosis of the condition.
A study published in the Neurogastroenterology & Motility journal in November 2024 stated that among the surveyed primary healthcare physicians in the US and Europe, 80% of them have the perception that 80% of the IBS patients are underdiagnosed in a primary healthcare setting. This underdiagnosis can significantly restrain the market growth by limiting the number of patients who receive appropriate treatment.
Global Irritable Bowel Syndrome Treatment Market Segment Analysis
The global irritable bowel syndrome treatment market is segmented based on disease type, drug class, and region.
Secretagogues in the drug class segment accounted for 32.9% of the market share in 2024 in the global irritable bowel syndrome treatment market
Secretagogues are a class of products that act by stimulating the release of bodily substances like hormones, fluids, enzymes, etc. In irritable bowel syndrome, the secretagogues act by inducing the release of intestinal fluids, which will aid in improving the bowel movement and reducing constipation. These drugs are currently approved by the regulatory bodies, such as the FDA, for use in IBS patients. These include drugs such as linaclotide (Linzess/Constella), lubiprostone (Amitiza), and plecanatide (Trulance). These drugs combinedly generated approximately 1.2 billion sales in 2024.
Due to the presence of brand exclusivity, manufacturers hold greater power in deciding the product price, hence generating higher revenues for their products. Although not widely adopted across the world, and majority of the patient population prefers the generic medication, especially in low & middle-income countries, this segment is poised to grow due to increasing awareness, clinical efficacy, and expansion into growing markets.
Global Irritable Bowel Syndrome Treatment Market Geographical Analysis
North America dominated the irritable bowel syndrome treatment market with the highest share of 45.3% in 2024
The disease burden of IBS is high in North America, especially in the U.S., due to an aging population, increasing stress levels among the population, unhealthy eating habits, mental health conditions, and many other factors. According to the American College of Gastroenterology, 1 in every 20 people in the US suffers from IBS.
In addition to this high disease burden, the U.S. boasts its advanced healthcare industry. There are several advanced drugs available in the U.S. market that are approved specifically for the condition. Manufacturers are constantly involved in launching novel therapies for IBS in the country. For instance, in April 2022, Ardelyx, Inc. announced the U.S. launch of IBSRELA for the treatment of IBS-C in adults. This drug acts by inhibiting NHE3 (Sodium-Hydrogen Exchanger 3), a novel mechanism targeting to treat constipation in IBS patients. This drug has become the first to be approved in the U.S. after 10 years, that is focusing on a novel mechanism.
Moreover, the most popular drugs for IBS, i.e., secretagogues, are widely available in the United States, and in fact, they generate a major portion of their revenue from the country. For instance, linaclotide sold under the brand name Linzess, by Ironwood Pharmaceuticals, Inc. and AbbVie, has generated a total sales of 954 million in 2024, out of which 96% is from the United States. This represents the highest for advanced therapies in the United States. All these factors strongly contribute to the region’s dominance in the global irritable bowel syndrome treatment market.
Global Irritable Bowel Syndrome Treatment Market Competitive Landscape (Major Players)
The major players in the irritable bowel syndrome treatment market are Procter & Gamble, Haleon Group of Companies., Teva Pharmaceutical Industries Ltd., Ironwood Pharmaceuticals, Inc., AbbVie., Salix Pharmaceuticals, Foundation Consumer Brands., Kenvue Brands LLC., Pfizer Inc., Upsher-Smith Laboratories, LLC., Sanofi, Bayer AG, Atlantis Consumer Healthcare Inc., Alfasigma Group, Takeda Pharmaceutical Company Limited., and Ardelyx. among others.
Global Irritable Bowel Syndrome Treatment Market Key Development
- In May 2024, Ardelyx, Inc. produced additional data supporting the clinical benefits of IBSRELA (tenapanor), a first-in-class drug approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. The data was presented at the 2024 Digestive Disease Week Conference (DDW), held in Washington.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Disease Type
2.4. Snippet by Drug Class
2.5. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Irritable Bowel Syndrome
3.1.1.2. Rising Novel Product Approvals
3.1.2. Restraints
3.1.2.1. Availability of Limited Treatment Options
3.1.2.2. Underdiagnosis of IBS
3.1.3. Opportunities
3.1.3.1. Increasing Patient Awareness and Advocacy Programs
3.1.3.2. Development of Microbiome-Based Therapies
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. Latin America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Pipeline Analysis
4.9. Epidemiology Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
5. GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISEASE TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
5.1.2. Market Attractiveness Index, By Disease Type
5.2. IBS with Diarrhea (IBS-D) *
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. IBS with Constipation (IBS-C)
5.4. Mixed-Presentation IBS (IBS-M)
5.5. Undefined IBS (IBS-U)
6. GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DRUG CLASS
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
6.1.2. Market Attractiveness Index, By Drug Class
6.2. Antispasmodics*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Antidiarrheal Medication
6.4. Laxatives
6.5. Antibiotics
6.6. Antidepressants
6.7. Fiber Supplements
6.8. Secretagogues
6.9. Others
7. GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
7.1.2. Market Attractiveness Index, By Region
7.2. North America
7.2.1. Introduction
7.2.2. Key Region-Specific Dynamics
7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.2.5.1. U.S.
7.2.5.2. Canada
7.2.5.3. Mexico
7.3. Europe
7.3.1. Introduction
7.3.2. Key Region-Specific Dynamics
7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.3.5.1. Germany
7.3.5.2. U.K.
7.3.5.3. France
7.3.5.4. Spain
7.3.5.5. Italy
7.3.5.6. Rest of Europe
7.4. South America
7.4.1. Introduction
7.4.2. Key Region-Specific Dynamics
7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.4.5.1. Brazil
7.4.5.2. Argentina
7.4.5.3. Rest of South America
7.5. Asia-Pacific
7.5.1. Introduction
7.5.2. Key Region-Specific Dynamics
7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.5.5.1. China
7.5.5.2. India
7.5.5.3. Japan
7.5.5.4. South Korea
7.5.5.5. Rest of Asia-Pacific
7.6. Middle East and Africa
7.6.1. Introduction
7.6.2. Key Region-Specific Dynamics
7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
8. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
8.1. Competitive Overview and Key Market Players
8.2. Market Share Analysis and Positioning Matrix
8.3. Strategic Partnerships, Mergers & Acquisitions
8.4. Key Developments in Product Portfolios and Innovations
8.5. Company Benchmarking
9. COMPANY PROFILES
9.1. Procter & Gamble*
9.1.1. Company Overview
9.1.2. Product Portfolio
9.1.2.1. Product Description
9.1.2.2. Product Key Performance Indicators (KPIs)
9.1.2.3. Historic and Forecasted Product Sales
9.1.2.4. Product Sales Volume
9.1.3. Financial Overview
9.1.3.1. Company Revenue’s
9.1.3.2. Geographical Revenue Shares
9.1.3.3. Revenue Forecasts
9.1.4. Key Developments
9.1.4.1. Mergers & Acquisitions
9.1.4.2. Key Product Development Activities
9.1.4.3. Regulatory Approvals, etc.
9.1.5. SWOT Analysis
9.2. Haleon Group of Companies.
9.3. Teva Pharmaceutical Industries Ltd.
9.4. Ironwood Pharmaceuticals, Inc.
9.5. AbbVie.
9.6. Salix Pharmaceuticals
9.7. Foundation Consumer Brands.
9.8. Kenvue Brands LLC.
9.9. Pfizer Inc.
9.10. Upsher-Smith Laboratories, LLC.
9.11. Sanofi
9.12. Bayer AG
9.13. Atlantis Consumer Healthcare Inc.
9.14. Alfasigma Group
9.15. Takeda Pharmaceutical Company Limited.
9.16. Ardelyx.
LIST NOT EXHAUSTIVE
10. APPENDIX
10.1. About Us and Services
10.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Disease Type
2.4. Snippet by Drug Class
2.5. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Irritable Bowel Syndrome
3.1.1.2. Rising Novel Product Approvals
3.1.2. Restraints
3.1.2.1. Availability of Limited Treatment Options
3.1.2.2. Underdiagnosis of IBS
3.1.3. Opportunities
3.1.3.1. Increasing Patient Awareness and Advocacy Programs
3.1.3.2. Development of Microbiome-Based Therapies
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. Latin America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Pipeline Analysis
4.9. Epidemiology Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
5. GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISEASE TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
5.1.2. Market Attractiveness Index, By Disease Type
5.2. IBS with Diarrhea (IBS-D) *
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. IBS with Constipation (IBS-C)
5.4. Mixed-Presentation IBS (IBS-M)
5.5. Undefined IBS (IBS-U)
6. GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DRUG CLASS
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
6.1.2. Market Attractiveness Index, By Drug Class
6.2. Antispasmodics*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Antidiarrheal Medication
6.4. Laxatives
6.5. Antibiotics
6.6. Antidepressants
6.7. Fiber Supplements
6.8. Secretagogues
6.9. Others
7. GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
7.1.2. Market Attractiveness Index, By Region
7.2. North America
7.2.1. Introduction
7.2.2. Key Region-Specific Dynamics
7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.2.5.1. U.S.
7.2.5.2. Canada
7.2.5.3. Mexico
7.3. Europe
7.3.1. Introduction
7.3.2. Key Region-Specific Dynamics
7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.3.5.1. Germany
7.3.5.2. U.K.
7.3.5.3. France
7.3.5.4. Spain
7.3.5.5. Italy
7.3.5.6. Rest of Europe
7.4. South America
7.4.1. Introduction
7.4.2. Key Region-Specific Dynamics
7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.4.5.1. Brazil
7.4.5.2. Argentina
7.4.5.3. Rest of South America
7.5. Asia-Pacific
7.5.1. Introduction
7.5.2. Key Region-Specific Dynamics
7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
7.5.5.1. China
7.5.5.2. India
7.5.5.3. Japan
7.5.5.4. South Korea
7.5.5.5. Rest of Asia-Pacific
7.6. Middle East and Africa
7.6.1. Introduction
7.6.2. Key Region-Specific Dynamics
7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
8. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
8.1. Competitive Overview and Key Market Players
8.2. Market Share Analysis and Positioning Matrix
8.3. Strategic Partnerships, Mergers & Acquisitions
8.4. Key Developments in Product Portfolios and Innovations
8.5. Company Benchmarking
9. COMPANY PROFILES
9.1. Procter & Gamble*
9.1.1. Company Overview
9.1.2. Product Portfolio
9.1.2.1. Product Description
9.1.2.2. Product Key Performance Indicators (KPIs)
9.1.2.3. Historic and Forecasted Product Sales
9.1.2.4. Product Sales Volume
9.1.3. Financial Overview
9.1.3.1. Company Revenue’s
9.1.3.2. Geographical Revenue Shares
9.1.3.3. Revenue Forecasts
9.1.4. Key Developments
9.1.4.1. Mergers & Acquisitions
9.1.4.2. Key Product Development Activities
9.1.4.3. Regulatory Approvals, etc.
9.1.5. SWOT Analysis
9.2. Haleon Group of Companies.
9.3. Teva Pharmaceutical Industries Ltd.
9.4. Ironwood Pharmaceuticals, Inc.
9.5. AbbVie.
9.6. Salix Pharmaceuticals
9.7. Foundation Consumer Brands.
9.8. Kenvue Brands LLC.
9.9. Pfizer Inc.
9.10. Upsher-Smith Laboratories, LLC.
9.11. Sanofi
9.12. Bayer AG
9.13. Atlantis Consumer Healthcare Inc.
9.14. Alfasigma Group
9.15. Takeda Pharmaceutical Company Limited.
9.16. Ardelyx.
LIST NOT EXHAUSTIVE
10. APPENDIX
10.1. About Us and Services
10.2. Contact Us
LIST OF TABLES
Table 1 Global Irritable Bowel Syndrome Treatment Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Million)
Table 2 Global Irritable Bowel Syndrome Treatment Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Million)
Table 3 Global Irritable Bowel Syndrome Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Million)
Table 4 Global Irritable Bowel Syndrome Treatment Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Million)
Table 5 Global Irritable Bowel Syndrome Treatment Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 6 Global Irritable Bowel Syndrome Treatment Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Million)
Table 7 Global Irritable Bowel Syndrome Treatment Market Value, By Drug Class, 2022-2033 (US$ Million)
Table 8 Global Irritable Bowel Syndrome Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Million)
Table 9 Global Irritable Bowel Syndrome Treatment Market Value, By Region, 2022-2033 (US$ Million)
Table 10 North America Irritable Bowel Syndrome Treatment Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 11 North America Irritable Bowel Syndrome Treatment Market Value, By Drug Class, 2022-2033 (US$ Million)
Table 12 North America Irritable Bowel Syndrome Treatment Market Value, By Country, 2022-2033 (US$ Million)
Table 13 South America Irritable Bowel Syndrome Treatment Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 14 South America Irritable Bowel Syndrome Treatment Market Value, By Drug Class, 2022-2033 (US$ Million)
Table 15 South America Irritable Bowel Syndrome Treatment Market Value, By Country, 2022-2033 (US$ Million)
Table 16 Europe Irritable Bowel Syndrome Treatment Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 17 Europe Irritable Bowel Syndrome Treatment Market Value, By Drug Class, 2022-2033 (US$ Million)
Table 18 Europe Irritable Bowel Syndrome Treatment Market Value, By Country, 2022-2033 (US$ Million)
Table 19 Asia-Pacific Irritable Bowel Syndrome Treatment Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 20 Asia-Pacific Irritable Bowel Syndrome Treatment Market Value, By Drug Class, 2022-2033 (US$ Million)
Table 21 Asia-Pacific Irritable Bowel Syndrome Treatment Market Value, By Country, 2022-2033 (US$ Million)
Table 22 Middle East and Africa Irritable Bowel Syndrome Treatment Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 23 Middle East and Africa Irritable Bowel Syndrome Treatment Market Value, By Drug Class, 2022-2033 (US$ Million)
Table 24 Middle East and Africa Irritable Bowel Syndrome Treatment Market Value, By Country, 2022-2033 (US$ Million)
Table 25 Procter & Gamble: Overview
Table 26 Procter & Gamble: Product Portfolio
Table 27 Procter & Gamble: Key Developments
Table 28 Haleon Group of Companies.: Overview
Table 29 Haleon Group of Companies.: Product Portfolio
Table 30 Haleon Group of Companies.: Key Developments
Table 31 Teva Pharmaceutical Industries Ltd.: Overview
Table 32 Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 33 Teva Pharmaceutical Industries Ltd.: Key Developments
Table 34 Ironwood Pharmaceuticals, Inc.: Overview
Table 35 Ironwood Pharmaceuticals, Inc.: Product Portfolio
Table 36 Ironwood Pharmaceuticals, Inc.: Key Developments
Table 37 AbbVie.: Overview
Table 38 AbbVie.: Product Portfolio
Table 39 AbbVie.: Key Developments
Table 40 Salix Pharmaceuticals: Overview
Table 41 Salix Pharmaceuticals: Product Portfolio
Table 42 Salix Pharmaceuticals: Key Developments
Table 43 Foundation Consumer Brands.: Overview
Table 44 Foundation Consumer Brands.: Product Portfolio
Table 45 Foundation Consumer Brands.: Key Developments
Table 46 Kenvue Brands LLC.: Overview
Table 47 Kenvue Brands LLC.: Product Portfolio
Table 48 Kenvue Brands LLC.: Key Developments
Table 49 Pfizer Inc.: Overview
Table 50 Pfizer Inc.: Product Portfolio
Table 51 Pfizer Inc.: Key Developments
Table 52 Upsher-Smith Laboratories, LLC.: Overview
Table 53 Upsher-Smith Laboratories, LLC.: Product Portfolio
Table 54 Upsher-Smith Laboratories, LLC.: Key Developments
Table 55 Sanofi: Overview
Table 56 Sanofi: Product Portfolio
Table 57 Sanofi: Key Developments
Table 58 Bayer AG: Overview
Table 59 Bayer AG: Product Portfolio
Table 60 Bayer AG: Key Developments
Table 61 Atlantis Consumer Healthcare Inc.: Overview
Table 62 Atlantis Consumer Healthcare Inc.: Product Portfolio
Table 63 Atlantis Consumer Healthcare Inc.: Key Developments
Table 64 Alfasigma Group: Overview
Table 65 Alfasigma Group: Product Portfolio
Table 66 Alfasigma Group: Key Developments
Table 67 Takeda Pharmaceutical Company Limited.: Overview
Table 68 Takeda Pharmaceutical Company Limited.: Product Portfolio
Table 69 Takeda Pharmaceutical Company Limited.: Key Developments
Table 70 Ardelyx.: Overview
Table 71 Ardelyx.: Product Portfolio
Table 72 Ardelyx.: Key Developments
Table 1 Global Irritable Bowel Syndrome Treatment Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Million)
Table 2 Global Irritable Bowel Syndrome Treatment Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Million)
Table 3 Global Irritable Bowel Syndrome Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Million)
Table 4 Global Irritable Bowel Syndrome Treatment Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Million)
Table 5 Global Irritable Bowel Syndrome Treatment Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 6 Global Irritable Bowel Syndrome Treatment Market Value, By Drug Class, 2025, 2029 & 2033 (US$ Million)
Table 7 Global Irritable Bowel Syndrome Treatment Market Value, By Drug Class, 2022-2033 (US$ Million)
Table 8 Global Irritable Bowel Syndrome Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Million)
Table 9 Global Irritable Bowel Syndrome Treatment Market Value, By Region, 2022-2033 (US$ Million)
Table 10 North America Irritable Bowel Syndrome Treatment Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 11 North America Irritable Bowel Syndrome Treatment Market Value, By Drug Class, 2022-2033 (US$ Million)
Table 12 North America Irritable Bowel Syndrome Treatment Market Value, By Country, 2022-2033 (US$ Million)
Table 13 South America Irritable Bowel Syndrome Treatment Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 14 South America Irritable Bowel Syndrome Treatment Market Value, By Drug Class, 2022-2033 (US$ Million)
Table 15 South America Irritable Bowel Syndrome Treatment Market Value, By Country, 2022-2033 (US$ Million)
Table 16 Europe Irritable Bowel Syndrome Treatment Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 17 Europe Irritable Bowel Syndrome Treatment Market Value, By Drug Class, 2022-2033 (US$ Million)
Table 18 Europe Irritable Bowel Syndrome Treatment Market Value, By Country, 2022-2033 (US$ Million)
Table 19 Asia-Pacific Irritable Bowel Syndrome Treatment Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 20 Asia-Pacific Irritable Bowel Syndrome Treatment Market Value, By Drug Class, 2022-2033 (US$ Million)
Table 21 Asia-Pacific Irritable Bowel Syndrome Treatment Market Value, By Country, 2022-2033 (US$ Million)
Table 22 Middle East and Africa Irritable Bowel Syndrome Treatment Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 23 Middle East and Africa Irritable Bowel Syndrome Treatment Market Value, By Drug Class, 2022-2033 (US$ Million)
Table 24 Middle East and Africa Irritable Bowel Syndrome Treatment Market Value, By Country, 2022-2033 (US$ Million)
Table 25 Procter & Gamble: Overview
Table 26 Procter & Gamble: Product Portfolio
Table 27 Procter & Gamble: Key Developments
Table 28 Haleon Group of Companies.: Overview
Table 29 Haleon Group of Companies.: Product Portfolio
Table 30 Haleon Group of Companies.: Key Developments
Table 31 Teva Pharmaceutical Industries Ltd.: Overview
Table 32 Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 33 Teva Pharmaceutical Industries Ltd.: Key Developments
Table 34 Ironwood Pharmaceuticals, Inc.: Overview
Table 35 Ironwood Pharmaceuticals, Inc.: Product Portfolio
Table 36 Ironwood Pharmaceuticals, Inc.: Key Developments
Table 37 AbbVie.: Overview
Table 38 AbbVie.: Product Portfolio
Table 39 AbbVie.: Key Developments
Table 40 Salix Pharmaceuticals: Overview
Table 41 Salix Pharmaceuticals: Product Portfolio
Table 42 Salix Pharmaceuticals: Key Developments
Table 43 Foundation Consumer Brands.: Overview
Table 44 Foundation Consumer Brands.: Product Portfolio
Table 45 Foundation Consumer Brands.: Key Developments
Table 46 Kenvue Brands LLC.: Overview
Table 47 Kenvue Brands LLC.: Product Portfolio
Table 48 Kenvue Brands LLC.: Key Developments
Table 49 Pfizer Inc.: Overview
Table 50 Pfizer Inc.: Product Portfolio
Table 51 Pfizer Inc.: Key Developments
Table 52 Upsher-Smith Laboratories, LLC.: Overview
Table 53 Upsher-Smith Laboratories, LLC.: Product Portfolio
Table 54 Upsher-Smith Laboratories, LLC.: Key Developments
Table 55 Sanofi: Overview
Table 56 Sanofi: Product Portfolio
Table 57 Sanofi: Key Developments
Table 58 Bayer AG: Overview
Table 59 Bayer AG: Product Portfolio
Table 60 Bayer AG: Key Developments
Table 61 Atlantis Consumer Healthcare Inc.: Overview
Table 62 Atlantis Consumer Healthcare Inc.: Product Portfolio
Table 63 Atlantis Consumer Healthcare Inc.: Key Developments
Table 64 Alfasigma Group: Overview
Table 65 Alfasigma Group: Product Portfolio
Table 66 Alfasigma Group: Key Developments
Table 67 Takeda Pharmaceutical Company Limited.: Overview
Table 68 Takeda Pharmaceutical Company Limited.: Product Portfolio
Table 69 Takeda Pharmaceutical Company Limited.: Key Developments
Table 70 Ardelyx.: Overview
Table 71 Ardelyx.: Product Portfolio
Table 72 Ardelyx.: Key Developments
LIST OF FIGURES
Figure 1 Global Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 2 Global Irritable Bowel Syndrome Treatment Market Share, By Disease Type, 2025 & 2033 (%)
Figure 3 Global Irritable Bowel Syndrome Treatment Market Share, By Drug Class, 2025 & 2033 (%)
Figure 4 Global Irritable Bowel Syndrome Treatment Market Share, By Region, 2025 & 2033 (%)
Figure 5 Global Irritable Bowel Syndrome Treatment Market Y-o-Y Growth, By Disease Type, 2025-2033 (%)
Figure 6 IBS with Diarrhea (IBS-D) Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 7 IBS with Constipation (IBS-C) Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 8 Mixed-Presentation IBS (IBS-M) Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 9 Undefined IBS (IBS-U) Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 10 Global Irritable Bowel Syndrome Treatment Market Y-o-Y Growth, By Drug Class, 2025-2033 (%)
Figure 11 Antispasmodics Drug Class in Global Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 12 Antidiarrheal Medication Drug Class in Global Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 13 Laxatives Drug Class in Global Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 14 Antibiotics Drug Class in Global Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 15 Antidepressants Drug Class in Global Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 16 Fiber Supplements Drug Class in Global Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 17 Secretagogues Drug Class in Global Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 18 Others Drug Class in Global Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 19 Global Irritable Bowel Syndrome Treatment Market Y-o-Y Growth, By Region, 2025-2033 (%)
Figure 20 North America Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 21 North America Irritable Bowel Syndrome Treatment Market Share, By Disease Type, 2025 & 2033 (%)
Figure 22 North America Irritable Bowel Syndrome Treatment Market Share, By Drug Class, 2025 & 2033 (%)
Figure 23 North America Irritable Bowel Syndrome Treatment Market Share, By Country, 2025 & 2033 (%)
Figure 24 South America Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 25 South America Irritable Bowel Syndrome Treatment Market Share, By Disease Type, 2025 & 2033 (%)
Figure 26 South America Irritable Bowel Syndrome Treatment Market Share, By Drug Class, 2025 & 2033 (%)
Figure 27 South America Irritable Bowel Syndrome Treatment Market Share, By Country, 2025 & 2033 (%)
Figure 28 Europe Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 29 Europe Irritable Bowel Syndrome Treatment Market Share, By Disease Type, 2025 & 2033 (%)
Figure 30 Europe Irritable Bowel Syndrome Treatment Market Share, By Drug Class, 2025 & 2033 (%)
Figure 31 Europe Irritable Bowel Syndrome Treatment Market Share, By Country, 2025 & 2033 (%)
Figure 32 Asia-Pacific Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 33 Asia-Pacific Irritable Bowel Syndrome Treatment Market Share, By Disease Type, 2025 & 2033 (%)
Figure 34 Asia-Pacific Irritable Bowel Syndrome Treatment Market Share, By Drug Class, 2025 & 2033 (%)
Figure 35 Asia-Pacific Irritable Bowel Syndrome Treatment Market Share, By Country, 2025 & 2033 (%)
Figure 36 Middle East and Africa Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 37 Middle East and Africa Irritable Bowel Syndrome Treatment Market Share, By Disease Type, 2025 & 2033 (%)
Figure 38 Middle East and Africa Irritable Bowel Syndrome Treatment Market Share, By Drug Class, 2025 & 2033 (%)
Figure 39 Procter & Gamble: Financials
Figure 40 Haleon Group of Companies.: Financials
Figure 41 Teva Pharmaceutical Industries Ltd.: Financials
Figure 42 Ironwood Pharmaceuticals, Inc.: Financials
Figure 43 AbbVie.: Financials
Figure 44 Salix Pharmaceuticals: Financials
Figure 45 Foundation Consumer Brands.: Financials
Figure 46 Kenvue Brands LLC.: Financials
Figure 47 Pfizer Inc.: Financials
Figure 48 Upsher-Smith Laboratories, LLC.: Financials
Figure 49 Sanofi: Financials
Figure 50 Bayer AG: Financials
Figure 51 Atlantis Consumer Healthcare Inc.: Financials
Figure 52 Alfasigma Group: Financials
Figure 53 Takeda Pharmaceutical Company Limited.: Financials
Figure 54 Ardelyx.: Financials
Figure 1 Global Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 2 Global Irritable Bowel Syndrome Treatment Market Share, By Disease Type, 2025 & 2033 (%)
Figure 3 Global Irritable Bowel Syndrome Treatment Market Share, By Drug Class, 2025 & 2033 (%)
Figure 4 Global Irritable Bowel Syndrome Treatment Market Share, By Region, 2025 & 2033 (%)
Figure 5 Global Irritable Bowel Syndrome Treatment Market Y-o-Y Growth, By Disease Type, 2025-2033 (%)
Figure 6 IBS with Diarrhea (IBS-D) Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 7 IBS with Constipation (IBS-C) Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 8 Mixed-Presentation IBS (IBS-M) Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 9 Undefined IBS (IBS-U) Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 10 Global Irritable Bowel Syndrome Treatment Market Y-o-Y Growth, By Drug Class, 2025-2033 (%)
Figure 11 Antispasmodics Drug Class in Global Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 12 Antidiarrheal Medication Drug Class in Global Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 13 Laxatives Drug Class in Global Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 14 Antibiotics Drug Class in Global Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 15 Antidepressants Drug Class in Global Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 16 Fiber Supplements Drug Class in Global Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 17 Secretagogues Drug Class in Global Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 18 Others Drug Class in Global Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 19 Global Irritable Bowel Syndrome Treatment Market Y-o-Y Growth, By Region, 2025-2033 (%)
Figure 20 North America Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 21 North America Irritable Bowel Syndrome Treatment Market Share, By Disease Type, 2025 & 2033 (%)
Figure 22 North America Irritable Bowel Syndrome Treatment Market Share, By Drug Class, 2025 & 2033 (%)
Figure 23 North America Irritable Bowel Syndrome Treatment Market Share, By Country, 2025 & 2033 (%)
Figure 24 South America Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 25 South America Irritable Bowel Syndrome Treatment Market Share, By Disease Type, 2025 & 2033 (%)
Figure 26 South America Irritable Bowel Syndrome Treatment Market Share, By Drug Class, 2025 & 2033 (%)
Figure 27 South America Irritable Bowel Syndrome Treatment Market Share, By Country, 2025 & 2033 (%)
Figure 28 Europe Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 29 Europe Irritable Bowel Syndrome Treatment Market Share, By Disease Type, 2025 & 2033 (%)
Figure 30 Europe Irritable Bowel Syndrome Treatment Market Share, By Drug Class, 2025 & 2033 (%)
Figure 31 Europe Irritable Bowel Syndrome Treatment Market Share, By Country, 2025 & 2033 (%)
Figure 32 Asia-Pacific Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 33 Asia-Pacific Irritable Bowel Syndrome Treatment Market Share, By Disease Type, 2025 & 2033 (%)
Figure 34 Asia-Pacific Irritable Bowel Syndrome Treatment Market Share, By Drug Class, 2025 & 2033 (%)
Figure 35 Asia-Pacific Irritable Bowel Syndrome Treatment Market Share, By Country, 2025 & 2033 (%)
Figure 36 Middle East and Africa Irritable Bowel Syndrome Treatment Market Value, 2022-2033 (US$ Million)
Figure 37 Middle East and Africa Irritable Bowel Syndrome Treatment Market Share, By Disease Type, 2025 & 2033 (%)
Figure 38 Middle East and Africa Irritable Bowel Syndrome Treatment Market Share, By Drug Class, 2025 & 2033 (%)
Figure 39 Procter & Gamble: Financials
Figure 40 Haleon Group of Companies.: Financials
Figure 41 Teva Pharmaceutical Industries Ltd.: Financials
Figure 42 Ironwood Pharmaceuticals, Inc.: Financials
Figure 43 AbbVie.: Financials
Figure 44 Salix Pharmaceuticals: Financials
Figure 45 Foundation Consumer Brands.: Financials
Figure 46 Kenvue Brands LLC.: Financials
Figure 47 Pfizer Inc.: Financials
Figure 48 Upsher-Smith Laboratories, LLC.: Financials
Figure 49 Sanofi: Financials
Figure 50 Bayer AG: Financials
Figure 51 Atlantis Consumer Healthcare Inc.: Financials
Figure 52 Alfasigma Group: Financials
Figure 53 Takeda Pharmaceutical Company Limited.: Financials
Figure 54 Ardelyx.: Financials
